At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
What is the Effect of Intravenous Iron Supplementation on Cardiopulmonary Haemodynamics, Exercise Capacity and Quality of Life in Patients With IPAH and Iron Deficiency?
In Brief
A Phase 2 clinical trial evaluating Saline and Ferinject or CosmoFer for Pulmonary Arterial Hypertension and Iron Deficiency. Completed, enrolled 56 participants across 5 sites in 3 countries.
Detailed Summary
This study will establish whether intravenous iron replacement has clinical benefit in idiopathic pulmonary arterial hypertension. A 24-week double-blind, randomised, placebo-controlled, crossover study will investigate whether a single dose of 1g of Ferinject® or CosmoFer improves cardiopulmonary haemodynamics, exercise capacity and quality of life and is well-tolerated. IV iron formulation used in Europe - Ferinject IV iron formulation used in China - CosmoFer
Study Details
Timeline
Interventions
intravenous, no active drug
Intravenous, 1000 mg iron